|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0007584,
umls-concept:C0008976,
umls-concept:C0026926,
umls-concept:C0034656,
umls-concept:C0085415,
umls-concept:C0205253,
umls-concept:C1332714,
umls-concept:C1516635,
umls-concept:C1548602,
umls-concept:C1963724
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-7-5
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
In a prospective randomized, controlled trial in Uganda comparing the efficacy of antiretroviral therapy during tuberculosis therapy with the efficacy of tuberculosis therapy alone in HIV-infected patients with tuberculosis who have a CD4(+) cell count >350 cells/microL, it was found that antiretroviral therapy did not accelerate microbiologic, radiographic, or clinical responses to tuberculosis therapy: 18% of participants had sputum smears positive for Mycobacterium tuberculosis after 5 months of tuberculosis therapy, despite having had negative culture results. Trial registration. ClinicalTrials.gov identifier: NCT00078247 .
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-10051244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-11326818,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-12758197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-15115831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-16776454,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-17290042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-17928422,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-19339714,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-7862181,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-8769512,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20569064-9655723
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
359-62
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:20569064-Adult,
pubmed-meshheading:20569064-Anti-HIV Agents,
pubmed-meshheading:20569064-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:20569064-Antitubercular Agents,
pubmed-meshheading:20569064-CD4 Lymphocyte Count,
pubmed-meshheading:20569064-Female,
pubmed-meshheading:20569064-HIV Infections,
pubmed-meshheading:20569064-Humans,
pubmed-meshheading:20569064-Lung,
pubmed-meshheading:20569064-Male,
pubmed-meshheading:20569064-Mycobacterium tuberculosis,
pubmed-meshheading:20569064-Prospective Studies,
pubmed-meshheading:20569064-Radiography, Thoracic,
pubmed-meshheading:20569064-Sputum,
pubmed-meshheading:20569064-Treatment Outcome,
pubmed-meshheading:20569064-Tuberculosis,
pubmed-meshheading:20569064-Uganda
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count.
|
|
pubmed:affiliation |
Department of Medicine, University of California, San Francisco, CA, USA. gabriel.chamie@ucsf.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, N.I.H., Extramural
|
